N/A
N=20
A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma
Melanosis
Bottom Line
View on ClinicalTrials.gov: NCT01976273 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcome: Primary: Visual Analog Scale (VAS) of Improvement Rated by a Blinded Dermatologist From at Week 10 — 4.37; 4.62 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- 1064nm Q-switch Laser (Device); Glycolic Acid Peels (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Northwestern University
- Primary completion
- Jan 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visual Analog Scale (VAS) of Improvement Rated by a Blinded Dermatologist From at Week 10 |
4.37; 4.62 | — |
Summary
The purpose of this study is to find out the safety and effectiveness of 1064 Q-Switch Laser Therapy compared to Glycolic Acid Chemical Peels for the treatment of melasma.
Eligibility Criteria
Inclusion Criteria
- Subjects aged 18 years or older
- Subjects with at least a 2 x 2 cm patch of melasma on each side of the face (forehead or cheek)
- Subjects in general good health
- Subjects must be willing and able to understand and provide informed consent for the use of their tissue and communicate with the investigator
- Subjects must be willing to not apply other treatment options for melasma during the course of the study
Exclusion Criteria
- Subjects under 18 years of age
- Subjects who are pregnant and/or lactating
- Subjects who are unable to understand the protocol or to give informed consent
- Subjects diagnosed with mental illness
- Subjects who have concurrent active uncontrolled disease to facial area (i.e uncontrolled acne)
- Subjects who have had a chemical peel in the past 3 months
- Subjects who have used a prescribed retinoid in the past 3 months
- Subjects with a bleeding disorder
- Subjects with a history of abnormal wound healing
- Subjects with a history of abnormal scarring
- Subjects who report being allergic to glycolic acid
Data sourced from ClinicalTrials.gov (NCT01976273). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.